Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Grows By 55.8%

Key Points

• Short interest in Newron (OTCMKTS:NWPHF) rose by 55.8% in March to 112,375 shares, producing a staggering days-to-cover ratio of 6,610.3 days based on an average daily volume of 17 shares; about 0.6% of the company's shares are currently short sold.
• Shares opened at $20.00 and sit at a one-year low/high of $9.10/$20.00 with 50-day and 200-day moving averages of $11.49 and $10.11, and the company is a clinical-stage biopharma focused on CNS disorders whose lead marketed product is safinamide (Xadago) for Parkinson's disease.

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF - Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 112,375 shares, an increase of 55.8% from the March 15th total of 72,125 shares. Based on an average daily trading volume, of 17 shares, the days-to-cover ratio is currently 6,610.3 days. Currently, 0.6% of the company's shares are short sold.

Newron Pharmaceuticals Stock Performance

Shares of OTCMKTS:NWPHF opened at $20.00 on Tuesday. Newron Pharmaceuticals has a one year low of $9.10 and a one year high of $20.00. The company has a 50 day moving average of $11.49 and a 200-day moving average of $10.11.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company's research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron's lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.